查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1854166

非類固醇消炎劑市場按藥物類別、劑型、給藥途徑、製劑狀態、釋放類型、病患小組、適應症​​、最終用戶和分銷管道分類－2025-2032年全球預測

Non-steroidal Anti-inflammatory Drugs Market by Drug Class, Formulation, Route Of Administration, Prescription Status, Release Type, Patient Group, Indication, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，非類固醇消炎劑市場規模將達到 388.1 億美元，複合年成長率為 6.67%。

關鍵市場統計數據
基準年2024年 231.4億美元
預計年份：2025年 246.2億美元
預測年份 2032 388.1億美元
複合年成長率 (%) 6.67%

對影響非類固醇消炎劑臨床應用、分銷和生命週期管理的當前動態進行了清晰權威的介紹。

非類固醇消炎劑(NSAIDs) 在臨床實踐和消費者自我護理中仍然佔據核心地位，這主要歸因於全球持續存在的疼痛、發炎和慢性肌肉骨骼疾病負擔。本文概述了 NSAIDs 市場格局的變化，並重點闡述了患者期望、監管審查和供應鏈壓力如何相互作用，重塑產品開發和分銷的格局。

過去幾年，臨床醫生和患者對藥物的安全性、長期耐受性以及療效與副作用之間的權衡有了更深入的了解。同時，數位醫療平台和藥局零售的創新正在拓展患者的就醫途徑，並改變他們的購買模式。因此，製造商和醫療服務提供者必須在實證治療方法的選擇與實際考慮（例如藥物目錄收錄、報銷趨勢和實際用藥依從性）之間取得平衡。為此，價值鏈上的相關人員在重新思考臨床通訊、生命週期管理和分銷策略，以滿足不斷變化的需求，同時確保合規性和品質標準。

技術進步、不斷變化的法規以及患者期望的轉變如何重塑非類固醇消炎劑領域的競爭策略和產品創新

非類固醇消炎劑市場正經歷著由技術進步、監管變革和患者​​行為改變所驅動的重大變革。新型數位療法和遠端醫療正在改變診療和決策流程，為教育和處方管理開闢新的途徑。同時，藥物安全檢測和真實世界證據收集的進步正在加強安全性評估，並為附加檔更新和處方指南的製定提供依據。

製造商正透過優先研發差異化配方、最佳化藥物動力學特徵以及投資以患者為中心的包裝和依從性解決方案來應對挑戰。同時，支付方和採購機構要求更清晰的價值主張，他們越來越關注總成本和療效，而不僅僅是單價。此外，供應鏈多元化和本土化措施正在推動策略供應商關係的建立和庫存最佳化。總而言之，這些因素正在重塑競爭格局，並加速配方、給藥途徑和管道策略的創新。

評估累積關稅調整對美國供應鏈採購、成本管理和商業性定位的營運和策略影響

2025年，美國累積關稅調整給整個醫藥供應鏈帶來了巨大的成本壓力，影響了採購決策、定價策略和營運韌性。關稅相關的成本增加會沿著價值鏈層層傳遞，促使製造商和經銷商重新評估其供應商佈局，協商修訂供應商契約，並尋求替代原料來源，以維持利潤率和供應的連續性。

因此，企業採取了多種策略，包括整合擁有良好合規記錄的供應商、加快二級供應商的資格審核，以及評估區域製造能力，以降低跨境關稅的影響。這些調整促使企業更加重視總成本模型和庫存規劃，進而降低價格波動。同時，商務團隊正加強與付款方和主要採購負責人的溝通，以明確成本促進因素和價值差異化因素，從而為價格調整提供依據。展望未來，將關稅敏感性納入策略採購和情境規劃的企業，將更有能力在保障財務績效的同時，維持產品供應。

以細分市場主導的洞察，將分銷管道、給藥途徑、藥物類別、劑型和終端用戶動態與策略決策點連結起來。

我們細緻入微的市場細分框架揭示了臨床偏好、通路經濟和製劑選擇如何相互作用，從而影響產品的可行性和市場接受度。按分銷管道分類，我們檢視了非處方藥和處方箋市場，並發現了不同的需求促進因素：消費者自我護理的優先性決定了非處方藥的市場佔有率，而臨床指南和報銷政策則決定了處方箋的使用。按給藥途徑分類，我們檢視了口服、注射和外用市場，並揭示了給藥途徑如何影響安全性監測、病患依從性和製劑研發重點。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 推出一種新型緩釋性Ibuprofen製劑，用於慢性疼痛管理
  • 非類固醇抗發炎藥物與生物製藥聯合治療的研發正在取得進展，該療法旨在緩解發炎並減少副作用。
  • 擴大局部使用局部雙氯芬酸鈉凝膠治療老年患者局部骨關節炎的適用範圍
  • 推出人工智慧驅動的藥物警戒平台，用於監測與非類固醇抗發炎藥物使用相關的心血管風險
  • 為了提高患者在非處方藥市場的依從性，固定劑量對乙醯胺酚和Ibuprofen的組合藥物正在興起。
  • 促進美洛昔康注射微球製劑在術後止痛的監管
  • 加大對綠色化學製程的投資，以實現永續製造
  • 隨著加速術後恢復通訊協定的廣泛採用，術中靜脈注射非類固醇抗發炎藥物以減少鴉片類藥物的使用量增加。
  • 零售商在電子商務止痛藥領域轉向自有品牌和超值包裝，導致Ibuprofen和萘普生的價格競爭加劇。
  • 將CYP2C9和CYP2C8變異體的藥物遺傳學檢測納入考量，以實現高風險患者非類固醇抗發炎藥物的個人化選擇和劑量。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章非類固醇消炎劑市場（依藥物類別分類）

  • 乙酸衍生物
    • 雙氯芬酸鈉
    • Ketorolac
  • 費納梅特
    • 氟芬那酸
    • 甲芬那酸
  • 奧昔康
    • Piroxicam
    • 替諾昔康
  • 丙酸衍生物
    • 氟比洛芬
    • Ibuprofen
    • 酮洛芬
    • 萘普生
  • 水楊酸鹽
    • 阿斯匹靈
    • 二氟尼柳
  • 選擇性COX-2抑制劑（昔布類藥物）
    • 塞來昔布
    • 依托考昔

第9章 處方類非類固醇消炎劑市場

  • 膠囊
  • 乳霜/凝膠
  • 粉末
  • 藥片

第10章非類固醇消炎劑市場依給藥途徑分類

  • 口服
  • 腸外
  • 話題

第11章非類固醇消炎劑市場（依處方箋狀態分類）

  • 在商店
  • 僅限處方箋

第12章非類固醇消炎劑市場依釋放類型分類

  • 即時釋放
  • 改良釋放
    • 控釋
    • 延遲釋放/腸溶包衣
    • 緩釋性

第13章非類固醇消炎劑市場病患小組

  • 成人
  • 老年人
  • 孩子們

第14章非類固醇消炎劑市場依適應症分類

  • 急性疼痛
    • 牙痛
    • 肌肉骨骼損傷（扭傷/拉傷）
    • 術後疼痛
  • 僵直性脊椎炎
  • 月經
  • 發燒
  • 偏頭痛
  • 眼痛和炎症
  • 骨關節炎
  • 類風濕性關節炎

第15章非類固醇消炎劑市場（依最終用戶分類）

  • 門診手術中心
  • 居家照護
  • 醫院
  • 專科診所

第16章非類固醇消炎劑市場（依通路分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥局

第17章非類固醇消炎劑市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第18章非類固醇消炎劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第19章 各國非類固醇消炎劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第20章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Novartis AG
    • Bayer AG
    • Pfizer Inc.
    • Abbvie, Inc
    • Algen Healthcare Ltd.
    • Allegiant Health
    • Amgen Inc.
    • Amneal Pharmaceuticals LLC
    • Arcutis Biotherapeutics, Inc.
    • Astellas Pharma Inc.
    • AstraZeneca PLC
    • Bristol-Myers Squibb Company
    • Clearsynth Labs Limited
    • Genentech, Inc. by F. Hoffmann-La Roche AG
    • GlaxoSmithKline PLC
    • Johnson & Johnson Services, Inc.
    • Pharbest Pharmaceuticals, Inc.
    • Sanofi SA
    • Spectrum Chemical Mfg. Corp.
    • Sun Pharmaceutical Industries Ltd.
    • Teikoku Seiyaku Co., Ltd.
    • Boehringer Ingelheim GmbH
    • Daiichi Sankyo Company, Limited
    • Eisai Co., Ltd.
    • Gilead Sciences, Inc.
    • Eli Lilly and Company
    • Incyte Corporation
    • Merck KGaA
    • Takeda Pharmaceutical Co. Ltd.
    • Dr. Reddy's Laboratories Ltd.
    • Sandoz International GmbH
    • Viatris Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Verona Pharma plc
    • Hikma Pharmaceuticals PLC
    • EMS SA
    • BASF SE
Product Code: MRR-7C50F2739687

The Non-steroidal Anti-inflammatory Drugs Market is projected to grow by USD 38.81 billion at a CAGR of 6.67% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 23.14 billion
Estimated Year [2025] USD 24.62 billion
Forecast Year [2032] USD 38.81 billion
CAGR (%) 6.67%

A clear and authoritative introduction to the current dynamics influencing clinical use, distribution, and lifecycle management of non-steroidal anti-inflammatory drugs

Non-steroidal anti-inflammatory drugs (NSAIDs) continue to occupy a central role in clinical practice and consumer self-care, driven by a persistent global burden of pain, inflammation, and chronic musculoskeletal conditions. This introduction frames the evolving context in which NSAIDs operate, highlighting how patient expectations, regulatory scrutiny, and supply chain pressures intersect to reshape product development and distribution dynamics.

Over the past several years, clinicians and patients have grown more discerning about safety profiles, long-term tolerability, and the therapeutic trade-offs between efficacy and adverse effects. Concurrently, digital health platforms and pharmacy retail innovations have broadened access pathways and altered purchasing patterns. In turn, manufacturers and healthcare providers must balance evidence-based therapeutic selection with pragmatic considerations such as formulary positioning, reimbursement trends, and real-world adherence. As a result, stakeholders across the value chain are rethinking clinical messaging, lifecycle management, and distribution strategies to meet shifting demand while maintaining compliance and quality standards.

How technological advances, regulatory evolution, and shifting patient expectations are reshaping competitive strategies and product innovation in the NSAID arena

The landscape for non-steroidal anti-inflammatory drugs is undergoing transformative shifts driven by technology, regulatory evolution, and changes in patient behavior. Emerging digital therapeutics and telemedicine have altered the points of care and decision-making, creating new touchpoints for education and prescription management. At the same time, advances in pharmacovigilance and real-world evidence collection are elevating safety assessment and informing label updates and prescribing guidelines.

Manufacturers are responding by prioritizing differentiated formulations, refining pharmacokinetic profiles, and investing in patient-centric packaging and adherence solutions. In parallel, payers and procurement organizations are demanding clearer value propositions, which increasingly emphasize total cost of care and outcomes rather than unit price alone. Moreover, supply chain diversification and onshoring initiatives are prompting strategic supplier relationships and inventory optimization. Taken together, these forces are reshaping competitive positioning and accelerating innovation across formulation, route of administration, and channel strategies.

Assessing the operational and strategic repercussions of cumulative tariff adjustments on supply chain sourcing, cost management, and commercial positioning in the US context

In 2025, cumulative tariff adjustments within the United States introduced material cost pressures across pharmaceutical supply chains, influencing sourcing decisions, pricing strategies, and operational resilience. Tariff-related cost increases can cascade through the value chain, prompting manufacturers and distributors to reassess supplier footprints, negotiate revised supplier agreements, and explore alternative raw material sources to preserve margins and supply continuity.

Consequently, organizations have pursued a mix of tactics, including consolidating suppliers with robust compliance track records, accelerating qualification of secondary suppliers, and evaluating regional manufacturing capacities to reduce exposure to cross-border duties. These adjustments have prompted magnified focus on total landed cost models and inventory planning to buffer volatility. At the same time, commercial teams have intensified dialogue with payers and major purchasers to articulate cost drivers and value differentiators that justify pricing adjustments. Looking forward, firms that integrate tariff sensitivity into strategic procurement and scenario planning will be better positioned to maintain product availability while safeguarding financial performance.

Segment-driven insights that connect distribution channel, administration route, drug class, formulation types, and end-user dynamics to strategic decision points

A nuanced segmentation framework reveals where clinical preferences, channel economics, and formulation choices intersect to influence product viability and adoption. Based on Distribution Channel, the market is studied across Over The Counter and Prescription, highlighting divergent demand drivers where consumer self-care priorities shape OTC traction while clinical guidelines and reimbursement determine prescription utilization. Based on Route Of Administration, the market is studied across Oral, Parenteral, and Topical, underscoring how administration mode influences safety monitoring, patient adherence, and formulation development priorities.

Based on Drug Class, the market is studied across COX-2 Inhibitors and Nonselective COX Inhibitors, reflecting distinct efficacy and safety trade-offs that inform therapeutic positioning and regulatory scrutiny. Based on Formulation, the market is studied across Capsules, Creams, Gels, Powders, Suspensions, Tablets, and Transdermal Patches, each of which carries unique manufacturing, stability, and patient-preference implications. Based on End User, the market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, demonstrating how procurement cycles, dispensing protocols, and patient access differ by channel. Integrating these segmentation lenses reveals clear vectors for differentiation in R&D investment, marketing focus, and supply chain design, and it clarifies the levers that drive product uptake and clinical acceptance across diverse care settings.

Regional intelligence explaining how distinct regulatory frameworks, payer dynamics, and care models drive differentiated strategies across global geographies

Regional dynamics continue to shape regulatory approaches, reimbursement pathways, and adoption patterns for non-steroidal anti-inflammatory therapies, and a regionally attuned strategy is essential for commercial success. In the Americas, stakeholders navigate a complex interplay of payer-driven access controls, consolidated distribution networks, and high rates of consumer engagement with OTC analgesics, requiring tailored evidence generation and value communication. In Europe, Middle East & Africa, regulatory frameworks and healthcare financing models vary markedly across jurisdictions, which drives differentiated product registration strategies and localized evidence packages to meet heterogeneous standards and procurement processes.

In the Asia-Pacific region, demographic shifts toward aging populations, expanding primary care infrastructure, and strong growth in e-pharmacy adoption are converging to increase demand for both prescription and OTC NSAID formulations. Across all regions, local manufacturing capabilities, regulatory timelines, and supply chain resilience inform launch sequencing and portfolio prioritization. Therefore, commercial teams must align regional market access strategies with local clinical practice patterns and distribution realities, and they must invest in regulatory intelligence and stakeholder engagement to accelerate adoption while maintaining compliance.

Company-level strategies that prioritize supply reliability, product differentiation, and evidence-driven positioning to strengthen competitive advantage

Competitive dynamics in the NSAID space continue to favor organizations that combine reliable supply chains, clear safety messaging, and targeted clinical differentiation. Leading pharmaceutical companies are refining lifecycle strategies by extending formulations, pursuing novel delivery mechanisms, and investing in post-marketing safety studies that reinforce confidence among prescribers and patients. In addition, several firms are leveraging partnerships with specialty manufacturers and contract development organizations to accelerate time-to-market for value-added formulations, reduce capital intensity, and access technical expertise in transdermal and topical platforms.

Strategic alliances between branded manufacturers and retail or online pharmacy chains are becoming more prevalent to secure shelf placement and consumer visibility. At the same time, product stewardship and pharmacovigilance investments have become non-negotiable differentiators, particularly as regulators and payers demand robust real-world evidence to support ongoing approvals and label updates. Firms that demonstrate operational excellence, transparent safety data, and coherent value narratives will maintain stronger relationships with payers, clinicians, and distribution partners, and they will be better positioned to defend and extend commercial relevance.

Actionable strategic priorities and operational levers for industry leaders to mitigate risk, strengthen differentiation, and accelerate commercial performance

Industry leaders should act decisively to translate evolving dynamics into competitive advantage through targeted investments and operational refinement. Prioritize diversification of raw material and finished-goods sourcing to mitigate tariff exposure and geopolitical risk, and concurrently implement advanced scenario planning that quantifies the operational impact of supply disruptions. Enhance pharmacovigilance and real-world evidence generation programs to support safety narratives and to facilitate constructive engagement with regulators, payers, and prescribers.

Furthermore, accelerate investments in differentiated formulations and patient-centric delivery systems that address adherence challenges and unmet needs, and align commercial messaging to emphasize total therapeutic value rather than unit price. Strengthen partnerships with distribution channels-hospital systems, retail pharmacies, and online pharmacies-to secure preferred placement and to tailor promotional tactics to channel-specific buying behavior. Finally, embed sustainability and quality assurance into supplier selection and manufacturing practices to meet rising stakeholder expectations and to reduce long-term operational risk.

A transparent and reproducible research methodology combining primary stakeholder interviews and secondary evidence synthesis to support robust insights

The research underpinning this analysis combined structured primary interviews with a cross-section of stakeholders and rigorous secondary research across public regulatory filings, clinical literature, and industry publications. Primary engagements included discussions with clinicians, formulary decision-makers, procurement leads, and supply chain executives to surface practical challenges and decision criteria that influence adoption and procurement. Secondary sources were used to validate trends in prescribing behavior, regulatory updates, and distribution innovations, and to triangulate findings from primary interviews.

Analytical approaches included thematic synthesis of qualitative inputs, scenario-based supply chain modeling to assess tariff impacts, and comparative assessment of formulation and channel dynamics. Quality assurance processes involved cross-validation of key assertions with multiple sources and iterative review by subject-matter experts. This methodology ensured that strategic conclusions reflect real-world stakeholder priorities and that recommended actions are grounded in defensible evidence and operational feasibility.

Strategic conclusion emphasizing operational resilience, evidence-based differentiation, and aligned channel engagement to sustain competitive relevance

In conclusion, the NSAID landscape is in a period of pragmatic evolution rather than radical upheaval, with incremental shifts driven by regulatory emphasis on safety, changing care delivery models, and supply chain realignment. Manufacturers and commercial teams must navigate these changes with disciplined portfolio management, targeted formulation innovation, and enhanced engagement with payers and distribution partners. Stakeholders that integrate tariff sensitivity into procurement planning, invest in real-world safety evidence, and pursue patient-centric delivery formats will be better positioned to sustain relevance and meet clinician and consumer needs.

Moving forward, organizations should maintain a dual focus on near-term operational resilience and medium-term clinical differentiation. By harmonizing supply chain decisions with evidence generation and channel strategies, firms can reduce exposure to external shocks while creating durable competitive advantages. Ultimately, the most successful players will combine operational rigor with a clear articulation of clinical and economic value to secure trust among clinicians, payers, and patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Launch of novel extended-release subcutaneous ibuprofen formulations targeting chronic pain management
  • 5.2. Rising development of NSAID-biologic combination therapies to mitigate inflammation with reduced side effects
  • 5.3. Expansion of topical diclofenac gel adoption among geriatric patients for localized osteoarthritis relief
  • 5.4. Deployment of AI-driven pharmacovigilance platforms to monitor cardiovascular risks associated with NSAID usage
  • 5.5. Growth of fixed-dose paracetamol and ibuprofen co-formulations to improve patient adherence in over-the-counter markets
  • 5.6. Regulatory acceleration for injectable meloxicam microsphere formulations aimed at postoperative pain control
  • 5.7. Increasing investment in green chemistry processes for sustainable manufacturing of non-steroidal anti-inflammatory drugs
  • 5.8. Wider adoption of enhanced recovery after surgery protocols driving increased perioperative use of intravenous NSAIDs to reduce opioids
  • 5.9. Shift toward retailer private labels and value packs in e-commerce analgesics intensifying price competition for ibuprofen and naproxen
  • 5.10. Integration of pharmacogenetic testing for CYP2C9 and CYP2C8 variants to personalize NSAID choice and dosing in high-risk patients

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Non-steroidal Anti-inflammatory Drugs Market, by Drug Class

  • 8.1. Acetic Acid Derivatives
    • 8.1.1. Diclofenac
    • 8.1.2. Ketorolac
  • 8.2. Fenamates
    • 8.2.1. Flufenamic Acid
    • 8.2.2. Mefenamic Acid
  • 8.3. Oxicams
    • 8.3.1. Piroxicam
    • 8.3.2. Tenoxicam
  • 8.4. Propionic Acid Derivatives
    • 8.4.1. Flurbiprofen
    • 8.4.2. Ibuprofen
    • 8.4.3. Ketoprofen
    • 8.4.4. Naproxen
  • 8.5. Salicylates
    • 8.5.1. Aspirin
    • 8.5.2. Diflunisal
  • 8.6. Selective COX-2 Inhibitors (Coxibs)
    • 8.6.1. Celecoxib
    • 8.6.2. Etoricoxib

9. Non-steroidal Anti-inflammatory Drugs Market, by Formulation

  • 9.1. Capsules
  • 9.2. Creams/Gels
  • 9.3. Powders
  • 9.4. Tablets

10. Non-steroidal Anti-inflammatory Drugs Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Parenteral
  • 10.3. Topical

11. Non-steroidal Anti-inflammatory Drugs Market, by Prescription Status

  • 11.1. Over-The-Counter
  • 11.2. Prescription Only

12. Non-steroidal Anti-inflammatory Drugs Market, by Release Type

  • 12.1. Immediate-Release
  • 12.2. Modified-Release
    • 12.2.1. Controlled-Release
    • 12.2.2. Delayed-Release/Enteric-Coated
    • 12.2.3. Extended-Release

13. Non-steroidal Anti-inflammatory Drugs Market, by Patient Group

  • 13.1. Adults
  • 13.2. Geriatric
  • 13.3. Pediatric

14. Non-steroidal Anti-inflammatory Drugs Market, by Indication

  • 14.1. Acute Pain
    • 14.1.1. Dental Pain
    • 14.1.2. Musculoskeletal Injury (Sprain/Strain)
    • 14.1.3. Postoperative Pain
  • 14.2. Ankylosing Spondylitis
  • 14.3. Dysmenorrhea
  • 14.4. Fever/Pyrexia
  • 14.5. Migraine & Headache
  • 14.6. Ophthalmic Pain & Inflammation
  • 14.7. Osteoarthritis
  • 14.8. Rheumatoid Arthritis

15. Non-steroidal Anti-inflammatory Drugs Market, by End User

  • 15.1. Ambulatory Surgical Centers
  • 15.2. Homecare
  • 15.3. Hospitals
  • 15.4. Specialty Clinics

16. Non-steroidal Anti-inflammatory Drugs Market, by Distribution Channel

  • 16.1. Hospital Pharmacies
  • 16.2. Online Pharmacies
  • 16.3. Retail Pharmacies

17. Non-steroidal Anti-inflammatory Drugs Market, by Region

  • 17.1. Americas
    • 17.1.1. North America
    • 17.1.2. Latin America
  • 17.2. Europe, Middle East & Africa
    • 17.2.1. Europe
    • 17.2.2. Middle East
    • 17.2.3. Africa
  • 17.3. Asia-Pacific

18. Non-steroidal Anti-inflammatory Drugs Market, by Group

  • 18.1. ASEAN
  • 18.2. GCC
  • 18.3. European Union
  • 18.4. BRICS
  • 18.5. G7
  • 18.6. NATO

19. Non-steroidal Anti-inflammatory Drugs Market, by Country

  • 19.1. United States
  • 19.2. Canada
  • 19.3. Mexico
  • 19.4. Brazil
  • 19.5. United Kingdom
  • 19.6. Germany
  • 19.7. France
  • 19.8. Russia
  • 19.9. Italy
  • 19.10. Spain
  • 19.11. China
  • 19.12. India
  • 19.13. Japan
  • 19.14. Australia
  • 19.15. South Korea

20. Competitive Landscape

  • 20.1. Market Share Analysis, 2024
  • 20.2. FPNV Positioning Matrix, 2024
  • 20.3. Competitive Analysis
    • 20.3.1. Novartis AG
    • 20.3.2. Bayer AG
    • 20.3.3. Pfizer Inc.
    • 20.3.4. Abbvie, Inc
    • 20.3.5. Algen Healthcare Ltd.
    • 20.3.6. Allegiant Health
    • 20.3.7. Amgen Inc.
    • 20.3.8. Amneal Pharmaceuticals LLC
    • 20.3.9. Arcutis Biotherapeutics, Inc.
    • 20.3.10. Astellas Pharma Inc.
    • 20.3.11. AstraZeneca PLC
    • 20.3.12. Bristol-Myers Squibb Company
    • 20.3.13. Clearsynth Labs Limited
    • 20.3.14. Genentech, Inc. by F. Hoffmann-La Roche AG
    • 20.3.15. GlaxoSmithKline PLC
    • 20.3.16. Johnson & Johnson Services, Inc.
    • 20.3.17. Pharbest Pharmaceuticals, Inc.
    • 20.3.18. Sanofi S.A.
    • 20.3.19. Spectrum Chemical Mfg. Corp.
    • 20.3.20. Sun Pharmaceutical Industries Ltd.
    • 20.3.21. Teikoku Seiyaku Co., Ltd.
    • 20.3.22. Boehringer Ingelheim GmbH
    • 20.3.23. Daiichi Sankyo Company, Limited
    • 20.3.24. Eisai Co., Ltd.
    • 20.3.25. Gilead Sciences, Inc.
    • 20.3.26. Eli Lilly and Company
    • 20.3.27. Incyte Corporation
    • 20.3.28. Merck KGaA
    • 20.3.29. Takeda Pharmaceutical Co. Ltd.
    • 20.3.30. Dr. Reddy's Laboratories Ltd.
    • 20.3.31. Sandoz International GmbH
    • 20.3.32. Viatris Inc.
    • 20.3.33. Teva Pharmaceutical Industries Ltd.
    • 20.3.34. Verona Pharma plc
    • 20.3.35. Hikma Pharmaceuticals PLC
    • 20.3.36. EMS S.A.
    • 20.3.37. BASF SE

LIST OF FIGURES

  • FIGURE 1. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 17. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 19. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. MIDDLE EAST NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. ASEAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. GCC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. EUROPEAN UNION NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. BRICS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 34. G7 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 35. NATO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 36. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 37. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 38. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DICLOFENAC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DICLOFENAC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DICLOFENAC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DICLOFENAC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DICLOFENAC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DICLOFENAC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOROLAC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOROLAC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOROLAC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOROLAC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOROLAC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOROLAC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLUFENAMIC ACID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLUFENAMIC ACID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLUFENAMIC ACID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLUFENAMIC ACID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLUFENAMIC ACID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLUFENAMIC ACID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MEFENAMIC ACID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MEFENAMIC ACID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MEFENAMIC ACID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MEFENAMIC ACID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MEFENAMIC ACID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MEFENAMIC ACID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PIROXICAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PIROXICAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PIROXICAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PIROXICAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PIROXICAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PIROXICAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TENOXICAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TENOXICAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TENOXICAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TENOXICAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TENOXICAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TENOXICAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLURBIPROFEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLURBIPROFEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLURBIPROFEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLURBIPROFEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLURBIPROFEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLURBIPROFEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IBUPROFEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IBUPROFEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IBUPROFEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IBUPROFEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IBUPROFEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOPROFEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOPROFEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOPROFEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOPROFEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOPROFEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOPROFEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY NAPROXEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY NAPROXEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY NAPROXEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY NAPROXEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY NAPROXEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ASPIRIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ASPIRIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ASPIRIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ASPIRIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ASPIRIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ASPIRIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DIFLUNISAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DIFLUNISAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DIFLUNISAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DIFLUNISAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DIFLUNISAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DIFLUNISAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CELECOXIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CELECOXIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CELECOXIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CELECOXIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CELECOXIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CELECOXIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ETORICOXIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ETORICOXIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ETORICOXIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ETORICOXIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ETORICOXIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ETORICOXIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CREAMS/GELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CREAMS/GELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CREAMS/GELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CREAMS/GELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CREAMS/GELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CREAMS/GELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY POWDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY POWDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY POWDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY POWDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY POWDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION ONLY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION ONLY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION ONLY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION ONLY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION ONLY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION ONLY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IMMEDIATE-RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IMMEDIATE-RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IMMEDIATE-RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IMMEDIATE-RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IMMEDIATE-RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IMMEDIATE-RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CONTROLLED-RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CONTROLLED-RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CONTROLLED-RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CONTROLLED-RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CONTROLLED-RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CONTROLLED-RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DELAYED-RELEASE/ENTERIC-COATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DELAYED-RELEASE/ENTERIC-COATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DELAYED-RELEASE/ENTERIC-COATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DELAYED-RELEASE/ENTERIC-COATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DELAYED-RELEASE/ENTERIC-COATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DELAYED-RELEASE/ENTERIC-COATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY EXTENDED-RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY EXTENDED-RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY EXTENDED-RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY EXTENDED-RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY EXTENDED-RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY EXTENDED-RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DENTAL PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DENTAL PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DENTAL PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DENTAL PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DENTAL PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DENTAL PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MUSCULOSKELETAL INJURY (SPRAIN/STRAIN), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MUSCULOSKELETAL INJURY (SPRAIN/STRAIN), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MUSCULOSKELETAL INJURY (SPRAIN/STRAIN), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MUSCULOSKELETAL INJURY (SPRAIN/STRAIN), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MUSCULOSKELETAL INJURY (SPRAIN/STRAIN), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLO